Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize

A solid tumor is an organ‐like entity comprised of neoplastic cells and non‐transformed host stromal cells embedded in an extracellular matrix. The expression of various genes is influenced by interactions among these cells, surrounding matrix, and their local physical and biochemical microenvironment. The products encoded by these genes, in turn, control the pathophysiological characteristics of the tumor, and give rise to the abnormal organization, structure, and function of tumor blood vessels. These abnormalities contribute to heterogeneous blood flow, vascular permeability, and microenvironment. Proliferating tumor cells produce solid stress which compresses blood and lymphatic vessels. As a result of vessel leakiness and lack of functional lymphatics, interstitial fluid pressure is significantly elevated in solid tumors. Each of these abnormalities forms a physiological barrier to the delivery of therapeutic agents to tumors. Furthermore, the metabolic microenvironment in tumors such as hypoxia and acidosis hinder the efficacy of anti‐tumor treatments such as radiation therapy and chemotherapy. A judicious application of anti‐angiogenic therapy has the potential to overcome these problems by normalizing the tumor vessels and making them more efficient for delivery of oxygen and drugs. Combined anti‐angiogenic and conventional therapies have shown promise in the clinic. J. Cell. Biochem. 101: 937–949, 2007. © 2006 Wiley‐Liss, Inc.

[1]  E. Rofstad,et al.  Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. , 2006, Cancer research.

[2]  Tatiana V. Petrova,et al.  Lymphangiogenesis in development and human disease , 2005, Nature.

[3]  H. Dvorak.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Rakesh K. Jain,et al.  Transport of molecules across tumor vasculature , 2004, Cancer and Metastasis Reviews.

[5]  D. Cheresh,et al.  Pathophysiological consequences of VEGF-induced vascular permeability , 2005, Nature.

[6]  S. Larson,et al.  “Artificial Lymphatic System”: A New Approach to Reduce Interstitial Hypertension and Increase Blood Flow, pH and pO2 in Solid Tumors , 2000, Annals of Biomedical Engineering.

[7]  M Intaglietta,et al.  Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  R K Jain,et al.  Fluorescence ratio imaging measurement of pH gradients: calibration and application in normal and tumor tissues. , 1993, Microvascular research.

[9]  Lei Xu,et al.  Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis. , 2006, Cancer research.

[10]  Dai Fukumura,et al.  Role of Microenvironment on Gene Expression, Angiogenesis and Microvascular Function in Tumors , 2005 .

[11]  V. Grégoire,et al.  Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[13]  Marc Dellian,et al.  Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  Koichi Hattori,et al.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? , 2002, Nature Reviews Cancer.

[15]  R. K. Jain,et al.  Vessels of death or life. , 2001, Scientific American.

[16]  S. Heiland,et al.  Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. , 2005, Cancer research.

[17]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[18]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[19]  R. Jain,et al.  Differential CD146 expression on circulating versus tissue endothelial cells in rectal cancer patients: implications for circulating endothelial and progenitor cells as biomarkers for antiangiogenic therapy. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R K Jain,et al.  Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. , 1994, Cancer research.

[21]  I. Fidler,et al.  Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. , 2001, Journal of the National Cancer Institute.

[22]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[23]  Rakesh K. Jain,et al.  Pathology: Cancer cells compress intratumour vessels , 2004, Nature.

[24]  P. Okunieff,et al.  Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. , 1989, Cancer research.

[25]  Geert M. P. van Kempen,et al.  Fluorescence Ratio Imaging , 1995 .

[26]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[27]  R K Jain,et al.  Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. , 2001, Cancer research.

[28]  Ricky T. Tong,et al.  Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer , 2004, Nature Medicine.

[29]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[30]  Rakesh K Jain,et al.  Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics , 2002, Science.

[31]  R. Xavier,et al.  Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.

[32]  Dai Fukumura,et al.  Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. , 2006, Cancer research.

[33]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[34]  R. Jain,et al.  Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Harold E. Dvorak,et al.  Tumor Architecture and Targeted Delivery , 2000 .

[36]  P. Vaupel,et al.  Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.

[37]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[38]  R K Jain,et al.  Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. , 1999, Cancer research.

[39]  Florey,et al.  The endothelial cell. , 1966, British medical journal.

[40]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[41]  E. Starling,et al.  The Anatomy and Physiology of Capillaries , 1923, Nature.

[42]  M. Dewhirst,et al.  Concepts of oxygen transport at the microcirculatory level. , 1998, Seminars in radiation oncology.

[43]  A. Bikfalvi,et al.  Tumor angiogenesis , 2020, Advances in cancer research.

[44]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[45]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[46]  Quynh-Thu Le,et al.  Lysyl oxidase is essential for hypoxia-induced metastasis , 2006, Nature.

[47]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[48]  L. Gerweck,et al.  Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics , 2006, Molecular Cancer Therapeutics.

[49]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[50]  K. Rubin,et al.  Inhibition of TGF-β modulates macrophages and vessel maturation in parallel to a lowering of interstitial fluid pressure in experimental carcinoma , 2005, Laboratory Investigation.

[51]  E. Goldmann.  The Growth of Malignant Disease in Man and the Lower Animals, with special reference to the Vascular System. , 1907, Proceedings of the Royal Society of Medicine.

[52]  P. Choyke,et al.  Imaging of angiogenesis: from microscope to clinic , 2003, Nature Medicine.

[53]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. , 1996, Nature medicine.

[54]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[55]  R K Jain,et al.  Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[56]  Janice M. Y. Brown,et al.  The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. , 1999, Cancer research.

[57]  Dai Fukumura,et al.  Peritumor Lymphatics Induced by Vascular Endothelial Growth Factor-C Exhibit Abnormal Function , 2004, Cancer Research.

[58]  P. Gullino,et al.  Angiogenesis and oncogenesis. , 1978, Journal of the National Cancer Institute.

[59]  R K Jain,et al.  Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. , 1997, The American journal of pathology.

[60]  P. Carmeliet,et al.  Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. , 2001, Cancer research.

[61]  Lei Xu,et al.  Tumour biology: Herceptin acts as an anti-angiogenic cocktail , 2002, Nature.

[62]  I. Tannock,et al.  Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. , 1997, British Journal of Cancer.

[63]  N. Fusenig,et al.  Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. , 2005, Cancer research.

[64]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[65]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[66]  Melody A. Swartz,et al.  Interstitial Flow as a Guide for Lymphangiogenesis , 2003, Circulation research.

[67]  L. H. Gray,et al.  The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy , 1955, British Journal of Cancer.

[68]  P. Carmeliet,et al.  Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis (vol 394, pg 485, 1998) , 1998 .

[69]  R. Jain,et al.  Acidic Extracellular pH Induces Vascular Endothelial Growth Factor (VEGF) in Human Glioblastoma Cells via ERK1/2 MAPK Signaling Pathway , 2002, The Journal of Biological Chemistry.

[70]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[71]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[72]  R. Skalak,et al.  Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.

[73]  B Landuyt,et al.  Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11 , 2003, British Journal of Cancer.

[74]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[75]  Ricky T. Tong,et al.  Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.